The life cycle of c-Myc: From synthesis to degradation

Cell Cycle

Volumn 3, Issue 9, 2004, Pages 1131-1135

  Sears, Rosalie C ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

c Myc; ERK; GSK 3 ; Pin1; PP2A; Ras; Serine 62; Stability; Threonine 58

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PIN1 PROLYL ISOMERASE; PROLINE; PROLYL ISOMERASE; RAF PROTEIN; RAS PROTEIN; SERINE; THREONINE; UNCLASSIFIED DRUG;

CANCER; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; DEPHOSPHORYLATION; HUMAN; HUMAN CELL; LIFE CYCLE; ONCOGENE C MYC; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; PROTEIN STABILITY; REVIEW;

EID: 13944252067     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.9.1145     Document Type: Review

References (63)

1. Cole MD. The myc oncogene: Its role in transformation and differentiation. Annu Rev Genet 1986; 20:361-84.
2. Luscher B, Eisenman RN. New light on Myc and Myb. Part I. Myc. Genes Dev 1990; 4:2025-35.
3. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene 1999; 18:2967-87.
4. Kelly K, Cochran BH, Stiles CD, Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983; 35:603-10.
5. Jones TR, Cole MD. Rapid cytoplasmic turnover of c-myc mRNA: Requirement of the 3′ untranslated sequences. Mol Cell Biol 1987; 7:4513-21.
6. Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell 1999; 3:169-79.
7. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18:3004-16.
8. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc one gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79:7824-7.
9. Dalla-Favera R, Wong-Staal F, Gallo RC. One gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient. Nature 1982; 299:61-3.
10. Spencer CA, Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 1991; 56:1-48.
11. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Adv Cancer Res 2002; 84:81-154.
12. Spotts GD, Hann SR. Enhanced translation and increased turnover of c-myc proteins occur during differentiation of murine erythroleukemia cells. Mol Cell Biol 1990; 10:3952-64.
13. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69:119-28.
14. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004; 6:308-18.
15. Flinn EM, Busch CM, Wright AP. Myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome. Mol Cell Biol 1998; 18:5961-9.
16. Gross-Mesilary S, Reinstein E, Bercovich B, Tobias KE, Schwartz AL, Kahana C, et al. Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc Natl Acad Sci USA 1998; 95:8058-63.
17. Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: Cancer-associated and transforming mutations stabilize Myc. EMBO J 1999; 18:717-26.
18. Hoyt MA. Eliminating all obstacles: Regulated proteolysis in the eukaryotic cell cycle. Cell 1997; 91:149-51.
19. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol 2000; 18:621-63.
20. 1-S transition: The SCF connection. Curr Opin Genet Dev 1998; 8:36-42.
21. Henriksson M, Bakardjiev A, Klein G, Luscher B. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene 1993; 8:3199-209.
22. Lutterbach B, Hann SR. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 1994; 14:5510-22.
23. Pulverer BJ, Fishet C, Vousden K, Littlewood T, Evan G, Woodgett JR. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 1994; 9:59-70.
24. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14:2501-14.
25. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993; 5:56-61.
26. Smith-Sorensen B, Hijmans EM, Beijersbergen RL, Bernards R. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins. J Biol Chem 1996; 271:5513-8.
27. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000; 95:2104-10.
28. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: Stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000; 20:2423-35.
29. Papas TS, Lautenberger JA. Sequence curiosity in v-myc oncogene. Nature 1985; 318:237.
30. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 2003; 278:51606-12.
31. Mumby MC, Walter G. Protein serine/threonine phosphatases: Structure, regulation, and functions in cell growth. Physiol Rev 1993; 73:673-99.
32. Janssens V, Goris J. Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochemical Journal 2001; 353:417-39.
33. Virshup DM. Protein phospharase 2A: A panoply of enzymes. Curr Opin Cell Biol 2000; 12:180-5.
34. Sears R, Ohtani K, Nevins JR. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol Cell Biol 1997; 17:5227-35.
35. Cook D, Fry MJ, Hughes K, Sumathipala R, Woodgett JR, Dale TC. Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling pathway which involves a protein kinase C. EMBO J 1996; 15:4526-36.
36. Silverstein AM, Barrow CA, Davis AJ, Mumby MC. Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc Natl Acad Sci USA 2002; 19:19.
37. Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 1999; 283:2089-91.
38. Sontag E, Fedorov S, Kamibayashi C, Robbins D, Cobb M, Mumby M. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell 1993; 75:887-97.
39. Ruediger R, Pham HT, Walter G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene 2001; 20:1892-9.
40. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996; 271:11059-62.
41. 2/M cell-cycle checkpoint. Nature 1997; 385:454-8.
42. Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, Stoller G, et al. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell 2000; 6:873-83.
43. Stukenberg PT, Kirschner MW. Pin1 acts catalytically to promote a conformational change in Cdc25. Mol Cell 2001; 7:1071-83.
44. Cho JH, Johnson GV. Primed phosphorylation of tau at thr231 by glycogen synthase kinase 3beta (GSK3β) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem 2004; 88:349-58.
45. Liou YC, Ryo A, Lee SW, Lu KP. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. J Biol Chem 2002; 277:47976-9.
46. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499-511.
47. Ryo A, Liou Y, et al. Prolyl isomerase Pin1: A catalyst for oncogenesis and a potential therapeutic target for cancer. Journal of Cell Science 2003; 116:773-83.
48. Pang R, Yuen J, Yuen MF, Lai CL, Lee TK, Man K, et al. PIN1 overexpression and bera-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 2004; 23:4182-6.
49. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Perkova V, et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 2001; 20:3459-72.
50. Ryo A, Liou YC, Wulf G, Nakamura M, Lee SW, Lu KP. PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol 2002; 22:5281-95.
51. Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R, et al. Pin1 links the activities of c-Ab1 and p300 in regulating p73 function. Mol Cell 2004; 14:625-36.
52. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S et al. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genoroxic insults. Nature 2002; 419:853-7.
53. Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, et al. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 2002; 419:849-53.
54. Lu PJ, Zhou XZ, Liou YC, Noel JP, Lu KP. Critical role of WW domain phosphorylation in regulating phosphoserine binding activity and Pin1 function. J Biol Chem 2002; 277:2381-4.
55. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79:13-21.
56. Pickart CM. Mechanisms underlying ubiquirinarion. Annu Rev Biochem 2001; 70:503-33.
57. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003; 11:1189-200.
58. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell 2003; 11:1177-88.
59. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004; 23:2116-25.
60. Welcker M, Orian A, Jin J, Grim JA, Harper JW, Eisenman RN, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation- dependent c-Myc protein degradation. Proc Natl Acad Sci USA 2004; 101:9085-90.
61. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW et al. Phosphorylarion-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001; 294:173-7.
62. Strohmaiet H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413:316-22.
63. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 2002; 22:2111-23.